FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR
FRA:22UA (3/7/2025, 7:00:00 PM)
101.6
-2.5 (-2.4%)
The current stock price of 22UA.DE is 101.6 EUR. In the past month the price decreased by -11.03%. In the past year, price increased by 22.5%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B | ||
1MRNA.MI | MODERNA INC | N/A | 12.34B |
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6133
Company Website: https://www.biontech.com/
Investor Relations: https://investors.biontech.de/
Phone: 4949613190840
The current stock price of 22UA.DE is 101.6 EUR. The price decreased by -2.4% in the last trading session.
The exchange symbol of BIONTECH SE-ADR is 22UA and it is listed on the Deutsche Boerse Ag exchange.
22UA.DE stock is listed on the Deutsche Boerse Ag exchange.
27 analysts have analysed 22UA.DE and the average price target is 134.32 EUR. This implies a price increase of 32.21% is expected in the next year compared to the current price of 101.6. Check the BIONTECH SE-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIONTECH SE-ADR (22UA.DE) has a market capitalization of 24.36B EUR. This makes 22UA.DE a Large Cap stock.
BIONTECH SE-ADR (22UA.DE) currently has 6133 employees.
BIONTECH SE-ADR (22UA.DE) has a support level at 101.59 and a resistance level at 112.64. Check the full technical report for a detailed analysis of 22UA.DE support and resistance levels.
The Revenue of BIONTECH SE-ADR (22UA.DE) is expected to decline by -38.23% in the next year. Check the estimates tab for more information on the 22UA.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
22UA.DE does not pay a dividend.
BIONTECH SE-ADR (22UA.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).
ChartMill assigns a technical rating of 1 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE turns out to be only a medium performer in the overall market: it outperformed 65.34% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to 22UA.DE. 22UA.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS decreased by -117.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -2.08% | ||
ROE | -2.44% | ||
Debt/Equity | 0.01 |
ChartMill assigns a Buy % Consensus number of 79% to 22UA.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -185.35% and a revenue growth -38.23% for 22UA.DE